![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/Ionis-shutterstock_1884612922.jpg)
Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug
US-based biotechnology company Ionis Pharmaceuticals has published positive results from the multiple ascending dose (MAD) portion of the Phase I/II HALOS study of ION582, a drug designed to treat Angelman syndrome (AS). The international, open-label …